HK1132181A1 - Medical compositions for intravesical treatment of bladder cancer - Google Patents

Medical compositions for intravesical treatment of bladder cancer

Info

Publication number
HK1132181A1
HK1132181A1 HK09110869.8A HK09110869A HK1132181A1 HK 1132181 A1 HK1132181 A1 HK 1132181A1 HK 09110869 A HK09110869 A HK 09110869A HK 1132181 A1 HK1132181 A1 HK 1132181A1
Authority
HK
Hong Kong
Prior art keywords
formulation
bladder cancer
medical compositions
intravesical treatment
azaridinyl
Prior art date
Application number
HK09110869.8A
Other languages
English (en)
Inventor
Bastiaan Nuijen
Ernie Pfadenhauer
Jos F Beijen
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of HK1132181A1 publication Critical patent/HK1132181A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK09110869.8A 2001-11-01 2005-01-12 Medical compositions for intravesical treatment of bladder cancer HK1132181A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34444601P 2001-11-01 2001-11-01
HK05100230 2005-01-12

Publications (1)

Publication Number Publication Date
HK1132181A1 true HK1132181A1 (en) 2010-02-19

Family

ID=23350584

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09110869.8A HK1132181A1 (en) 2001-11-01 2005-01-12 Medical compositions for intravesical treatment of bladder cancer

Country Status (13)

Country Link
US (6) US6894071B2 (pt)
EP (3) EP1864660B1 (pt)
JP (1) JP4317452B2 (pt)
AT (2) ATE493126T1 (pt)
AU (1) AU2002350115A1 (pt)
CA (2) CA2789114C (pt)
CY (1) CY1111252T1 (pt)
DE (2) DE60238798D1 (pt)
DK (2) DK1864660T3 (pt)
ES (2) ES2384208T3 (pt)
HK (1) HK1132181A1 (pt)
PT (2) PT2060259E (pt)
WO (1) WO2003037314A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002350115A1 (en) * 2001-11-01 2003-05-12 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
AU2006230582A1 (en) * 2005-03-31 2006-10-05 Spectrum Pharmaceuticals, Inc. Indoloquinone tumor radiation sensitization
ATE540996T1 (de) 2005-06-06 2012-01-15 Univ British Columbia Polymerbasierter serumalbumin-ersatzstoff
AU2007213476B2 (en) * 2006-02-09 2013-03-28 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment involving determination of tumor enzyme level
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
MX2009009777A (es) * 2007-03-13 2009-11-26 Spectrum Pharmaceuticals Inc Administracion intravesical de apaziquone despues de reseccion transuretral para tratamiento de cancer.
GB0800311D0 (en) * 2008-01-09 2008-02-20 Cytosystems Ltd Apparatus and method for filtering biological material
ES2732150T3 (es) 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
EP2542613A4 (en) 2010-03-01 2013-12-11 Univ British Columbia DERIVATED HYPER BRANCHED POLYGLYCEROLS
NO2619331T3 (pt) * 2010-09-22 2018-07-28
EP2734187B1 (en) 2011-07-20 2018-09-05 UroGen Pharma Ltd. Materials and method for treating internal body cavities
EP2771320B1 (en) 2011-10-24 2016-06-22 Endo Pharmaceuticals Inc. Cyclohexylamines
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2015095128A1 (en) 2013-12-16 2015-06-25 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
CN104743887B (zh) * 2014-09-22 2016-03-23 巨石集团有限公司 一种玻璃纤维组合物及其玻璃纤维和复合材料
CA3037748A1 (en) 2016-09-30 2018-04-05 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
CN112220742A (zh) * 2019-07-15 2021-01-15 深圳艾欣达伟医药科技有限公司 稳定的ast-3424注射液制剂及制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
JPS54151134A (en) 1978-05-19 1979-11-28 Kureha Chem Ind Co Ltd Antitumorigenic agent
NL8001280A (nl) * 1980-03-04 1981-10-01 Philips Nv Lagedrukontladingslamp.
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
JPS60163621A (ja) 1984-02-02 1985-08-26 村上　俊文 紙製便座カバ−の製造方法
JPS60163821A (ja) 1984-02-03 1985-08-26 Tdk Corp フエライト粒子を含む薬剤用担体
JPS61189215A (ja) 1985-02-18 1986-08-22 Teijin Ltd ５−フルオロ−２′−デオキシウリジンエステル類の油状医薬組成物
ATE82961T1 (de) 1986-04-17 1992-12-15 Willem Nico Speckamp Indochinon-verbindungen.
US4871542A (en) 1987-04-30 1989-10-03 Ferring Service Center, N.V. Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
EP0331635A3 (en) 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
EP0338679A3 (en) 1988-03-24 1991-03-06 Genentech, Inc. Tumour necrosis factor in the treatment of bladder cancer
FR2629584B1 (fr) 1988-03-31 1993-06-04 France Etat Armement Dispositif de stabilisation pour un projectile a faible moment d'inertie longitudinal tire a partir d'un tube raye
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
PT93772A (pt) 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
US5237466A (en) 1989-11-02 1993-08-17 International Business Machines Corporation Method and apparatus for programmably controlling spindle synchronization and phase among disk drives in a storage subsystem
FI84874C (fi) 1989-11-02 1992-02-10 Valio Meijerien Foerfarande foer inkapsling av biologiskt aktiva aemnen, enligt metoden framstaelld kapsel, dess anvaendning och foder innehaollande den.
US5292516A (en) 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
JP3598049B2 (ja) 1992-09-18 2004-12-08 山之内製薬株式会社 ハイドロゲル徐放性製剤
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ES2145102T3 (es) 1993-09-09 2000-07-01 Takeda Chemical Industries Ltd Formulacion que comprende una sustancia antibacteriana y una sustancia antiulcerosa.
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5405622A (en) 1993-12-22 1995-04-11 Vernice; Joseph Gamma radiation resistant lubricating gel
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
ES2421306T3 (es) 1994-12-12 2013-08-30 Omeros Corporation Solución de irrigación y procedimiento para inhibir el dolor, la inflamación y los espasmos
US5749845A (en) 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
AU1166097A (en) 1995-12-21 1997-07-17 British Technology Group Limited Indoloquinone derivatives as bioreductive agents
US5985312A (en) 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
BR9708046A (pt) 1996-03-11 2000-01-04 Focal Inc Método para radioterapia local nim paciente e respectiva composição.
US5955096A (en) 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6251861B1 (en) 1996-06-27 2001-06-26 Takeda Chemical Industries, Ltd. Treatment of cerebral infarction using cyclic hexapeptides
JP2967734B2 (ja) * 1996-10-18 1999-10-25 日本電気株式会社 薄膜の形成方法
JP2001519787A (ja) 1997-04-03 2001-10-23 ポイント バイオメディカル コーポレイション 膀胱内ドラッグデリバリーシステム
US5854382A (en) 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
WO1999012548A1 (en) * 1997-09-08 1999-03-18 Theramark Limited Treatment of inflammatory conditions
US6156744A (en) 1998-03-19 2000-12-05 Cancer Research Campaign Tech (London) DT-diaphorase directed anti-tumor agents
CA2268640A1 (en) 1998-04-14 1999-10-14 Mitsuru Shiraishi Composition for preventing or treating ischemic disease
US6171610B1 (en) 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
US6476053B1 (en) 1998-05-05 2002-11-05 Astrazeneca Ab Mycobacterial inhibitors
IL124957A0 (en) 1998-06-16 1999-01-26 Univ Ben Gurion Active ingredient delivery systems and devices based on porous matrices
US6087396A (en) 1998-10-05 2000-07-11 Situs Corporation Oxybutynin formulations and method of use
GB9827034D0 (en) 1998-12-10 1999-02-03 Univ Manchester Delivery formulation
JP2000256182A (ja) 1999-03-03 2000-09-19 Kazuhiro Morimoto 抗菌製剤
WO2000067023A1 (en) 1999-04-29 2000-11-09 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
JP2003535061A (ja) 2000-05-31 2003-11-25 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー エンドセリン受容体拮抗剤および疼痛軽減特性を有する抗癲癇化合物または鎮痛剤の複合物
JP4323802B2 (ja) 2000-12-01 2009-09-02 エムジーアイ・ジーピー・インコーポレーテッド 化合物およびその使用
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
AU2002350115A1 (en) * 2001-11-01 2003-05-12 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
JP5184738B2 (ja) 2002-05-03 2013-04-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 修飾第ｖｉｉ因子の安定化された固体組成物
US20040009918A1 (en) 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN1729012B (zh) 2002-10-24 2013-05-22 伊利诺伊大学评议会 治疗实体瘤的组合物
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
AU2007213476B2 (en) 2006-02-09 2013-03-28 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment involving determination of tumor enzyme level

Also Published As

Publication number Publication date
EP2060259A1 (en) 2009-05-20
WO2003037314A2 (en) 2003-05-08
ES2384208T3 (es) 2012-07-02
CA2466148C (en) 2013-01-08
ATE455545T1 (de) 2010-02-15
US20030133954A1 (en) 2003-07-17
CA2466148A1 (en) 2003-05-08
US8648108B2 (en) 2014-02-11
CA2789114C (en) 2014-03-25
JP2005532986A (ja) 2005-11-04
EP2060259B1 (en) 2010-01-20
EP1864660B1 (en) 2010-12-29
EP1864660A2 (en) 2007-12-12
US20120252861A1 (en) 2012-10-04
AU2002350115A1 (en) 2003-05-12
ATE493126T1 (de) 2011-01-15
CA2789114A1 (en) 2003-05-08
PT2060259E (pt) 2010-04-26
US20050215615A1 (en) 2005-09-29
US20080166402A1 (en) 2008-07-10
WO2003037314A3 (en) 2003-10-16
US7977369B2 (en) 2011-07-12
EP1439835A2 (en) 2004-07-28
CY1111252T1 (el) 2015-08-05
DE60235214D1 (de) 2010-03-11
US20070010570A1 (en) 2007-01-11
DK2060259T3 (da) 2010-05-17
US6894071B2 (en) 2005-05-17
DK1864660T3 (da) 2011-02-21
DE60238798D1 (de) 2011-02-10
EP1864660A3 (en) 2008-04-23
JP4317452B2 (ja) 2009-08-19
PT1864660E (pt) 2011-03-31
ES2341922T3 (es) 2010-06-29
US20090076123A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
HK1132181A1 (en) Medical compositions for intravesical treatment of bladder cancer
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2004069335A3 (en) Magnetic implants to treat body tissue structures
WO2006034315A3 (en) Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
HK1103363A1 (en) Treatment of glycogen storage diseases type ii ii
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
AU2002223684A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
WO2003022852A3 (en) Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
YU17402A (sh) Nova spiroheterociklična jedinjenja upotrebljiva kao reverzibilni inhibitori cisteinskih proteaza
WO2001060347A3 (en) Method for treating ocular pain
WO2001052847A8 (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
EP1264603B8 (en) Use of L-polynucleotides for in vivo imaging
WO2002087503A3 (en) Compositions and methods for treating colorectal polyps and cancer
WO2003022203A3 (en) Products and methods for treating microbial infections
WO2003020221A3 (en) Method of treating cancerous disease
ZA200209835B (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites.
WO2003024486A1 (fr) Traitements de la perte osseuse
WO2002096317A3 (en) Method for treating glaucoma vi
CA2458932A1 (en) Methylene-4-azasteroids
ES2165747A1 (es) Depsipeptidos como inhibidores de resorcion de hueso.
UA33229A (uk) Спосіб деривації сечі після цистектомії

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191101